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Summary 
Carbohydrate antigens rarely provide target epitopes for cytotoxic T  lymphocytes (CTL). Di- 
sialoganglioside GD2 is a glycolipid expressed at high levels in human tumors and a small group 
of murine lymphomas (EL4, RBLS, RMA, RMA-S, A13, and BALBRVE). Immunization of 
C57B1/6 mice with irradiated EL4 cells stimulated a specific CTL response and protected these 
animals from engraftment of EL4 lymphoma. The CTL activity resided in the CD4-CD8 + 
population, was dependent on T cell receptor odB, and was not removed by anti-natural killer 
cell immunoabsorption, but was restricted to GD2 and H-2  b bearing targets. CTL activity could 
be completely inhibited by GDz-oligosaccharide-specific  monoclonal antibodies and their F(ab')2 
fragments, but not by immunoglobulin G3 myelomas or antibodies against GD3 or GM2. Soluble 
GD2 did not inhibit specific tumor lysis. RMA-S lymphoma cells (GD2+H-2b-TAP2 deficient) 
were resistant to GD2-specific CTL. Sialic acid-containing peptides eluted from EL4 lymphoma 
cells could (a) stabilize  H-2 molecules on RMA-S cells and (b) sensitize them for GD2-specific 
CTL. Control peptides (derived from vesicular stomatitis virus nucleoprotein peptide and GD2- 
negative lymphomas) could also  stabilize  H-2 on R/VIA-S, but were resistant to Gn2-specific 
CTL. These H-2-binding peptides could be purified by anti-GD2 affinity chromatography. We 
postulate a new class of naturally occurring epitopes for T cells where branched-chain oligosac- 
charides are linked to peptides with anchoring motifs for the major histocompatibility complex 
class I pocket. While analogous to the haptens trinitrophenyl and O-H-linked acetyl-glucosamine, 
the potential implications of natural carbohydrates as antigenic epitopes for CTL in biology are 
considerable. 
B 
inding  of peptide  antigens  to  MHC  class  I  proteins 
on APC is necessary for the activation of CTL precursors 
through recognition by TCR, interaction with adhesion mol- 
ecules,  and coactivation of other accessory proteins (1-3). 
Detailed structural analyses have identified unique octa- and 
nanopeptides that lodge specifically into the groove of class 
I rnolecules. Once activated, CTL will lyse targets carrying 
the specific peptide in association with the appropriate MHC 
class I molecules. Antigen systems involved in CTL activa- 
tion (1) have been primarily peptide antigens. In model systems, 
haptenic determinants (e.g., TNP groups) have been shown 
clearly to require a peptide backbone that interacts specifically 
with class I MHC antigen grooves (4).  However, no natu- 
rally occurring haptenic system has been described to date. 
Carbohydrate determinants have traditionally not been thought 
to function as target molecules for CTL, although they acti- 
vate B cells in humoral immune responses. Glycolipids are 
poor immunogens for antibody response (5).  Rare reports 
of T  cell response to glycolipid (e.g., GM3) have implicated 
the role of associated peptides (6).  Recently, Haurum et al. 
(7)  presented  the  first  evidence  of  immunogenicity  and 
specificity of synthetic O-glycosylated MHC-binding pep- 
tides. In this study, we describe evidence implicating a natu- 
rally occurring  GD2  oligosaccharide as  target  antigen  for 
CTL.  CTL  primed  to  GD2 +  tumors  killed  Gn2-bearing 
tumors that expressed the appropriate MHC class I mole- 
cules.  These  CTL  were  Thyl +  CD8 +  CD4- TCR-cz/3 +. 
Since GD2 oligosaccharide is a natural component of neu- 
ronal cells and human tumors, it offers a potential target for 
specific CTL in human diseases. 
Materials  and Methods 
Mice.  C57B1/6, BALB/c, and CAF1 mice were purchased from 
Jackson Laboratory (Bar Harbor, ME). BALB/c nu/nu mice were 
bred  at  Memorial  Sloan Kettering  Cancer  Center (MSKCC)  1. 
Tumor cells were planted (0.5-1  x  105 ceils in a volume of 100 
#1) subcutaneously into C57B1/6 mice. After implantation, tumor 
sizes (maximum height,  width, and length) were measured over 
time. 
Cell Lines.  EL4-IL2  (TIB181), EL4, and P815 were purchased 
from American Type Culture Collection (Rockville, MD). T2 and 
A13 were obtained from Dr. B. Cheeseboro (National Institute of 
Allergy and Infectious Diseases, Rocky Mountain Lab, Hamilton, 
MO). HFL/b was provided by Dr. Frank Lilly (Albert Einstein 
1 Abbreviations used in  this paper: MSKCC,  Memorial  Sloan Kettering 
Cancer Center; NP, nucleoprotein peptide; VSV, vesicular  stomatitis virus. 
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obtained from Dr.  Kenneth  Blank (Hahneman Medical School, 
Philadelphia,  PA);  FBL3 from Dr. Lloyd Law (National Cancer 
Institute, Bethesda, MD); RBL5 and BALBRVE from Dr. Shuji 
Ikegami (Meiji Institute of Health Science, Odawara, Japan); and 
RMA and RMA-S from Dr. Hans-Gustag Ljunggren (8; Karolinska 
Institute,  Stockholm,  Sweden).  EL4,  B6RV1,  B6RV2,  and 
BALBRVE were provided by Dr. Elizabeth Stockert (MSKCC). 
All cell lines were cultured in 10% defined calf serum (Hyclone 
Laboratories Inc., Logan, UT) in RPMI with 2 mM r-glutamine, 
100 U/ml of penicillin (Sigma Chemical Co., St. Louis, MO), 100 
~g/ml of streptomycin (Sigma Chemical Co.),  and 5%  CO2 in 
a 37~  humidified incubator.  A  G,2-negative EL4 cell line was 
prepared by subcloning. 
Antibodies.  Anti-GD2 mAbs were produced in our laboratory 
as previously reported (9).  They were manufactured by ascites in- 
duction in BALB/c or CAF1 mice and purified by protein A affi- 
nity chromatography (IgG) or Superose 12 (Pharmacia Inc., Pisca- 
taway, NJ) chromatography under hypotonic conditions (IgM). 3F8 
was an IgG3, and 3G6, 3A7,  and 5Fll  were IgMs. F(ab')2 frag- 
ments were prepared by pepsin digestion as previously reported (10). 
Anti-GD3 antibody (R24) was kindly provided by Dr. Alan Hough- 
ton  and  anti-GM2 (696)  antibody  by  Dr.  Philip  Livingston 
(MSKCC).  FLOPC21,  an  IgG3 myeloma,  was purchased  from 
Sigma Chemical Co.  TIB114 (N.S.7),  a hybridoma secreting an 
IgG~ control antibody, was obtained from American Type Culture 
Collection, and 6H12 (control IgM) was produced in our own lab- 
oratory. Rat antibodies against Thyl.2 (5.3-2.1),  CD4 (RM 4-5), 
CD8 (53-5.8),  NK, mouse mAb against H-2KbD  b (AF6-88.5)  and 
H-2KdD  d (SF1-1.1), and hamster anti-TCR-ce/B (H57-597) were 
purchased  from PharMingen  (San  Diego,  CA).  HBll  (anti-H- 
2KbD  b, clone 20-8-4S,  an IgG2a hybridoma) was purchased from 
American Type Culture Collection. Rat antiidiotypic mAbs were 
produced in nude mice as previously described (11). 
Indirect Immunofluorescence.  Surface  antigen  expression  was 
studied by immunofluorescence flow cytometry. Anti-H-2 (Phar- 
Mingen) and anti-G,2 antibodies were used at 2/~g per 106 cells. 
Antibodies against rat or mouse Ig (Tago, Inc., Burlingame, CA) 
were used according to the manufacturer's instructions.  106 cells 
were washed with PBS containing 0.02% sodium azide. After in- 
cubation with antibodies on ice for 30 min, the cells were washed 
and  reacted  with  fluorescein-labeled affinity-purified goat  anti- 
mouse/rat antibody on ice for 30 min. The cells were washed and 
resuspended in  100 #1 of 1%  formaldehyde after washing. 
CTL Induction and SICr Release Assay.  C57B1/6 mice were im- 
munized i.p. with EL4 cells irradiated at 12,000 fads. Spleen cells 
were harvested >t21 d after immunization and stimulated in vitro 
by irradiated EL4. Cytotoxic activity was measured 5-6 d after in 
vitro culture. In brief, 2  x  103 SlCr-labeled target cells were mixed 
with effector cells in a final volume of 0.2 ml of medium in 96-well 
flat-bottomed microtiter plates (Costar Corp., Cambridge, MA). 
The plates were incubated for 4 h at 37~  in 5% CO2 and then 
centrifuged.  100 #1 of assay supernatant was counted in a gamma 
counter. Target cell spontaneous chromium release ranged from 10 
to 25%. 
Immunoadsorption by Panning.  Using goat anti-rat or anti-mouse 
Ig (PharMingen) at 3.3/~g/ml, plastic culture dishes were coated 
as follows: 15 ml per 100-mm plate and 7 ml per 60-mm plate at 
4~  for at least 18 h. The antibodies were removed, and the plates 
were washed and blocked with PBS containing 10% BSA at 4~ 
for 2 h.  Anti-CD4,  CD8, Thyl.2,  or NK were incubated with 
mouse spleen cells at a final concentration of 2/~g per 107 cells 
per ml on ice for 30-60 rain. After washing the cells three times 
with cold PBS containing 2% BSA, the cells were added to goat 
antibody-coated plates and further incubated at 4~  for 1 h. Nonad- 
herent cells were panned again using identical steps.  All the ad- 
herent fractions were combined. 
Class I Molecule Stabilizing by Peptide.  RMA-S cells grown to 
a density of 106 cells per ml at 37~  were maintained at 25~  for 
36  h  in a container with 3%  CO2.  The cells were washed and 
resuspended to 106 cells per ml in 10% FCS-RPMI.  5-10/~g (in 
300-500/~1)  of vesicular stomatitis virus (VSV) nucleoprotein pep- 
tide (NPs2-sg, a kind gift from Dr. J. Nikolic-Zugic, MSKCC) or 
500/~1 of acid eluate from murine lymphoma cells was added per 
106 RMA-S cells. Cells were incubated at 25~  for 1 h and then 
at 37~  for 2 h before being separated into two aliquots: (a) for 
CTL assays, the treated cells were labeled with chromium at 37~ 
for 1 h, washed,  and used as targets in a 4-h SlCr release  assay; 
(b) a separate aliquot of cells was cultured for an additional  1 h 
at 37~  and class I MHC molecules were measured by indirect 
immunofluorescence. 
Acid Ehtion of  Peptides  frora Tumor Cell Su~ce.  EL4 cells were 
grown in F10 (RPMI 1640 containing 10% calf serum [Hyclone 
Laboratories, Inc.], 2 mM glutamine, 100 U/ml of penicillin,  and 
100 #g/m1 of streptomycin). For each preparative run,  109 viable 
murine lymphoma cells were pelleted and resuspended in 10 ml 
of 0.4% TFA (Sigma Chemical Co.) in PBS, pH 2, for 1 min at 
4~  with mixing, and the supernatant was collected by microcen- 
trifugation.  After neutralization with 1 M  Tris to a final pH of 
7, the extract was millipore filtered (0.2/~m) and then ultrafiltered 
(Amicon Inc., Beverly, MA) with cutoff limits of 10 kD and then 
frozen at  -80~  or used for RMA-S MHC class I stabilization 
experiments. For enzyme treatment, agarose-bound neuraminidase 
(Sigma Chemical Co.) and streptococcal protease (Sigma Chem- 
ical Co.) were washed in PBS and reacted with TFA tumor eluate 
at 0.1 U  of neuraminidase or 1 U  of protease per milliliter of ex- 
tract. After incubation at 37~  for 2 h, the reaction was allowed 
to continue overnight with mixing. The enzyme beads were re- 
moved by centrifugation. For control experiments, tumor extract 
was treated at 37~  for 2 h and at room temperature overnight 
but without  enzyme beads added. 
Immunoafl~nity Chromatography.  Antibody 3F8 was dialyzed in 
0.02 M sodium acetate, pH 5.0, containing 0.15 M sodium chlo- 
ride, and was reacted with 50:1 vol/vol ratio of 0.5 M NalO4 for 
60 min at room temperature.  1:20 vol/vol ratio of glycerol was 
added to neutralize the oxidizing agent for 10 rain. Oxidized anti- 
body was dialyzed in coupling buffer (0.1 M sodium acetate, 0.5 M 
Na2SO4, pH 4.5) at room temperature for 6 h  and was reacted 
with washed Affi-Prep Hz Hydrazide Support (Bio-Rad Laborato- 
ries, Richmond, CA) according to the manufacturer's instructions 
(1.5 mg of 3F8 for each milliliter of gel). Acid eluate was purified 
by anti-GD2 affinity chromatography using FPI.C (Pharmacia Inc.). 
0.5 M ammonium acetate was used to elute adsorbed peptides, which 
were dried by vacuum centrifugation  and redissolved  in PBS. 
Vaccination  Against EL4.  C57B1/6 mice were immunized with 
irradiated EL4 and then challenged with s.c. injection of tumori- 
genic EL4 tumor cells. Control mice were immunized with RMA-S 
and B6RV2 tumors. Engraftment was determined by periodic mea- 
surements using a fine caliper. 
Results 
Kinetics of Secondary CTL Response.  C57B1/6 mice were 
immunized i.p. (days 0 and 21) with irradiated H-2b-bearing 
tumor cells EL4, EL4-IL2, RBLS, or RMA, and then chal- 
lenged with s.c. injection of EL4 lymphoma 5-6 d afterwards. 
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immunized with saline,  B6RV2,  or  RMA-S  (both H-2  b) 
tumor cells showed earlier EL4 engraftment and higher mor- 
tality at 1 mo (Table 1). To study the protective immunity 
after i.p. injection of irradiated EL4 cells, spleen cells from 
C57B1/6 mice were boosted in vitro for 5 or 6 d and assayed 
with EL4 targets (Fig. 1). Specific lysis was consistently found 
and was inhibitable by anti-GD2 mAb 3F8. The kinetics of 
the in vitro-boosted CTL response was investigated over 5 d 
(days 3-8).  CTL activity first became detectable on day 4, 
peaked on days 5 to 6, and declined to half maximal killing 
by day 8 (Fig. 2). While most of the CTL activity was in- 
hibitable by 3F8 during the early part of the secondary re- 
sponse,  the degree of inhibition diminished substantially by 
day 8 of culture. 
Effector.  After 5 d of in vitro boost, effector ceils were 
depleted of specific populations by irnmunoabsorption. Using 
cell panning on mAb-coated plastic dishes, CTL activity was 
found in the adherent populations for both anti-Thyl and 
anti-CD8.  In contrast, CTL activity resided in the nonad- 
herent population after anti-CD4 immunoadsorption (Fig. 
3). Anti-NK panning did not eliminate specific  lysis. No differ- 
ences were found in the phenotypic characteristics  of CTL 
that were obtained by single immunization or hyperimmu- 
nization (data not shown). 
Requirement  of H-2 Molecules and TCR for  Tumor Killing. 
Spleen CTL from EL4-primed mice were boosted in vitro 
for 5 d and assayed on various tumor call lines (Table 2). Only 
target cells bearing GD2 and H-2  b molecules (EL4, RBL5, 
RMA, A13) were susceptible to lysis by the EL4-primed spleen 
CTL. RMA-S cells lacking surface class I antigens and GD2+ 
BALBP,  VE of a different H-2 background (H-2  a) resisted 
Table  1.  Protection from  Tumor Engraftment  after  Vaccination 
with EL4 
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Figure  1.  Specific  lysis  of EL4 targets measured  by slCr release. Spleen 
cells from EL4-immunized  C57B1/6 mice were cultured in the presence 
of irradiated EL4 cells for 5 or 6 d and then assayed  with EL4 targets. 
Solid circles, CTL after  5 d of in vitro boost (n = 15); solid squares, CTL 
after 6 d of in vitro boost (n =  12); open squares and circles, CTL in the 
presence of 3F8 inhibitor. 
BALBRVE of a different H-2 background (H-2  a) resisted 
killing by these CTL. Although most of the EL4-specific CTL 
activity was inhibited by 3F8 when assayed against various 
GD2 + targets, the inhibition was close to complete only for 
EL4-IL2. Inhibition by anti-H-2KbD  b mAb was consistent 
(Table 3) and dose dependent (Fig. 4), in contrast to anti-H- 
2KaD  d mAh, which was ineffective.  Anti-TCP,-a/B mAb 
also  strongly inhibited specific CTL activity. 
Target Antigen.  Anti-G,2 oligosaccharide  antibodies dur- 
ing the killing phase (irrespective  of isotype IgM vs IgG3) 
inhibited CTL activity consistently (Table 2) and in a dose- 
dependent manner (Fig.  5).  F(ab')2 fragments were almost 
as effective as the intact 3F8 mAb (Table 3 and Fig. 5). Con- 
trol mouse mAbs R.24 (IgG3 anti-GD3), 696 (IgM anti-Gva), 
FLOPC21 (IgG3 myeloma), and NS.7 (IgG3 myeloma) were 
Size* of tumor at 
Alive  NED 
Immunogen  n  2 wk  3 wk  1 mo  1 mo 
EL4  7  0 (0/7)  333  (2/7)  3/7  2/7 
RBL5  8  0 (0/8)  114 (3/8)  7/8  4/8 
EL4-IL2  8  0 (0/8)  716  (2/8)  6/8  4/8 
RMA  8  0 (0/8)  507 (7/8)  1/8  1/8 
RMA-S  8  625  (4/8)  898 (7/8)  2/8  1/8 
B6RV2  4  146 (3/4)  1,822  (4/4)  0/4  0/4 
None  7  126 (5/7)  978 (6/6)  0/7  0/7 
Mice were immunized  i.p. with 5 x  106 irradiated  (12,000 rads) tumor 
cells and boosted with the same number of tumor ceUs 21 d later. They 
were challenged  s.c. with 1@ EL4 cells 5-6 d afterwards. NED, no evi- 
dence of disease. 
* Size of tumor equals the (product of maximum height, width, and 
length)/2, arithmetic  means of tumors in tumor-bearing  mice. Numbers 
in parentheses  represent number of mice  bearing tumors over total num- 
ber of mice studied. 
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Figure  2.  Kinetics of CTL response. Spleen ceils ~'om EL4-immunized 
C57B1/6 mice were cultured in the presence of irradiated EL4 cells for 
3-8 d and then assayed  with EL4 targets. Solid circles and squares, specific 
lysis of EL4 targets; open circles and squares, specific  lysis  in the presence 
of anti-Cro2 antibody  (3F8, 10 tzg/mt) as inhibitor. 
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Figure  3.  Distribution of CTL by panning.  Spleen cells from EL4- 
immunized C57B1/6 mice were cultured in the presence of irradiated EL4 
cells for 5 d and then assayed with EL4 targets.  Solid bars, nonadherent 
population; open bars, adherent population, hatched  bars, adherent popula- 
tion in the presence of anti-Gin (3F8,  10/zg/ml) inhibitor. 
Table  2.  Percentage of Specific Lysis of Tumor Targets 
Percentage  Percentage 
Target  GD2  N*  of lysist  of Inh 
C57B1/6,  H-2  b 
EL4  +  4  45  80 
EL4-1L2  +  4  29  98 
RBL5  +  4  27  70 
RMA  +  4  29  69 
A13  +  4  38  89 
RMA-S  +  3  7  nd 
FBL3  -  2  <5  <5 
B6RV2  -  1  <5  nd 
BALB.B,  H-2  b 
HFL/b  4  <5  <5 
Table 3.  Percentage of Inhibition of Specific Lysis by Antibodies 
mAb  Specificity  n*  Mean*  (SE) 
Mouse  IgG 
~x 
20-8-4S  H-2  b  9  65  AF6-88.5J  (2) 
SF1-1.1  H-2 a  9  7  (2) 
H57-597s  TCR-ct/~  9  81  (2) 
3F8  GD2  9  68  (4) 
3F8-F(ab')2  GD2  6  47  (1) 
R24  Go3  6  3  (2) 
FLOPC21  -  6  3  (2) 
NS.7  SRBC  6  8  (2) 
6H12  Breast  CA  6  1  (1) 
Mouse  IgM 
3G6  GD2  9  52  (2) 
3A7  GD2  6  58  (5) 
5Fll  GD2  6  52  (13) 
696  GM2  6  1  (0) 
Rat  IgG 
AIG4  3F8 idiotype  3  7  (7) 
Idio2  3F8  idiotype  3  0  (0) 
2E6  Mouse  IgG3  3  3  (3) 
Spleen cells from EL4-immunized mice were cultured in vitro in the 
presence of irradiated  EL4 for 5 d and were used as effectors against EL4 
targets  at  an E/T ratio of either 100:1,  50:1,  or 25:1  in the presence 
of 10/~g/ml of inhibitor antibodies. 
* Number of inhibition experiments;  data at E/T ratios of 100:1, 50:1, 
and 25:1  were averaged. 
* Arithmetic mean. 
S Hamster IgG. 
CA,  carcinoma. 
BALB/c,  H-2 d 
BALBRVE  +  1  <5  <5 
T2  -  4  <5  <5 
HFL/d  -  4  <5  <5 
BALB.K,  H-2  k 
HFL/k  -  4  <5  <5 
DBA/2,  H-2q 
P815  -  1  (5  nd 
" Number of experiments. 
* Spleen cells from EL4-immunized mice were cultured in vitro in the 
presence of irradiated  EL4 for 5 d and used as effectors against the targets 
at E/T ratio of 50:1. 
%Ink,  percentage of lysis inhibitable  by 3F8;  nd, not done. 
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Figure 4.  Inhibition of specific  lysis by anti-H-2 antibodies. Spleen cells 
from EL4-immunized  C57B1/6 mice were cultured in the presence of ir- 
radiated  EL4 cells for 5 d and  then assayed with EL4 targets. Solid and 
open squares, E/T ratio  of 25:1; solid and open circles, E/T ratio of 50:1. 
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Figure 5.  Inhibition  of spedfic  lysis  by anti-GD2 antibody.  Effector  cells 
and targets as in Fig. 4. Solid circles and squares, E/T ratio of 100:1; open 
circles and squares, E/T ratio of 25:1; circles, whole 3F8 antibody;  squares, 
3F8 F(ab')2 fragments. 
ineffective  (Table 3).  Soluble  GD2 or GD3 antigens (0.1-20 
#g/ml) failed to inhibit CTL compared with ethanol con- 
trols; data not shown. Rat antiidiotypic mAb directed at 3F8 
also failed to inhibit CTL activity. In other control experi- 
ments,  anti-G,2 antibodies did not  nonspecifically  inhibit 
CTL activity from C57B1/6 mice immunized with P815 or 
B6RV2 tumor cell lines (data not shown). In addition, CTL 
activity was  not affected by panning with anti-GD2 mAb, 
eliminating  the  possibility  that  inhibition  was  mediated 
through GD2 on killer cells (data not shown). Neuramini- 
dase treatment of EL4 targets completely eliminated anti- 
GD2  antibody-inhibitable  CTL  activity;  however  GD2- 
independent killing was increased  (data not shown). 
Sialic Acid-containing PeFtide Was the Target  for CTL.  RMA-S 
cells  are  deficient in  tram-membrane  transporters  because 
of their defective  transporter-associated with antigen pro- 
cessing (TAP2) gene (12). Although both RMA-S (H-2  b-) 
and RMA (H-2  b+) expressed high levels of surface GD2, only 
the latter was sensitive to GD2-specific CTL induced by EL4. 
MHC class I antigens on RMA-S cells could be stabilized 
by exogenous VSV peptide, acid eluates from G,2 + or GD2- 
EL4 when measured by indirect immunofluorescence (Fig. 
6 A  and Table 4), but not if the acid eluate was treated by 
solid-phase protease (Fig. 6 B). Eluates from tumor cells sta- 
bilized  H-2  to  different degrees:  those  from  G,z+/IL2  - 
secreting and Gn2-negative  EL4 cell lines were comparable 
to VSV, both being more potent that the eluate from GD2 § 
EL4 cell line. In addition, only acid eluate from GD2 + EL4 
lines could sensitize RMA-S cells for killing by specific CTL, 
which was inhibitable by anti-GD2 antibodies. Neuramini- 
dase treatment of the acid eluate did not affect its ability to 
stabilize H-2 on RMA-S (Fig.  6 C  and Table 4) but elimi- 
nated its ability to sensitive RMA-S cells for killing by specific 
CTL. GD2 + EL4 acid eluate was purified by anti-GDz affinity 
chromatography (Fig. 6 C and Table 4). While affinity-purified 
fractions from GD2 + EL4 cells could stabilize H-2 on RMA-S 
cells, those from control acid eluate could not. In addition, 
fractions from GD2 + EL4 cells could sensitize RMA-S targets 
for killing by specific CTL. 
Discussion 
We have shown that CTL derived from mice immunized 
against  routine lymphoma EL4 reside  in  a  CD8+CD4 - 
NK- T cell population and will lyse tumor targets carrying 
cell  surface  ganglioside GD2. Specific lysis is  restricted to 
targets that share at least two antigens with EL4: the target 
antigen GD2 oligosaccharide  and MHC class I antigen H-2  b. 
TCR-o~/~ is required, and CTL interaction with antigens 
on tumor targets appears to be inhibitable by anti-GD2 anti- 
bodies but not by soluble GD2. The target antigen is sensi- 
tive to protease  and neuraminidase treatment and can be 
purified by anti-Gin affinity chromatography. We postulate 
a new class of epitopes for T cells where branched-chain car- 
bohydrate residues are linked to peptides that bind to the MHC 
class I pocket. While analogous to the hapten TNP, the poten- 
tial implications of carbohydrates as antigenic epitopes for 
CTL in biology are considerable. GD2 is expressed on human 
neuronal tissues as well as a wide spectrum of  human tumors; 
it provides  a unique model for studying T  cell recognition 
of carbohydrate antigens in both malignant and autoimmune 
diseases. 
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Figure 6.  Histograms  showing  stabilization  of H-2  b on RMAoS  cells, y axis = frequency;  x axis = fluorescence  channel. (.4) a, control acid eluate; 
b, VSV NP peptide 5/~g/ml; c-e represent acid eluates from GD2 + EL4, GD2 +/IL2-secreting  EL4, and GD2-negative  EL4, respectively.  (B) a, control 
acid eluate; b-d represent acid eluate from GD2 +/IL2-secreting EL4 cell line before and after treatment  with protease or neuraminidase,  respectively. 
(C) a, control acid eluate; b, VSV NP peptide; c and d represent acid eluate from GD2 + EL4 cell line before  and after  affinity  purification  on anti-GD2 
column. 
71  Zhao and Cheung Table 4.  Bioactivity of Eluted PeFtides 
Percentage 
CelI line  Treatment*  H-2  of Lysis 
R/VIA  None  +  29 
RMA-S  None  -  7 
RMA-S  VSV NP52-s9  +  2 
RMA-S  Sham extract*  -  6 
RMA-S  GD2 + EL4 extracts  +  30 
EL4-IL2 extract  +  31 
C~2- EL4 extract II  +  1 
RMA-S  EL4-IL2 extract 
+  NANA bead  I  +  1 
RMA-S  EL4-IL2 extract 
+  protease bead  -  1 
RMA-S  EL4 "peptides  ....  +  18 
RMA-S  Control**  -  5 
*  RMA-S or RMA cells were cultured for 48 h at 25~  The cells were 
washed and incubated with either medium alone or medium containing 
5-10/~g/ml of VSV peptide for 1 h at 25~  then 37~  for 3 h. H-2 
expression was measured by immunofluorescence. Spleen cells from 
EL-4-primed mice were boosted in vitro with irradiated EL4 cells for 
5 d and assayed with the cell lines as targets at E/T ratio of 50:1. 
* TFA/PBS neutralized  with Tris. 
S  TFA/PBS extract from GD2 + EL4 cell line. 
II TFA/PBS extract from GD2 + EL4 cell line. 
￿82  Acid eluate from GD2 + EL4 cells was treated with solid phase neur- 
aminidase (NANA). 
** EL4 "peptides": TFA/PBS eluate from GD2 + EL4 was purified by 
anti-GD2 a~nity chromatography; n  =  7; average lysis, 18%  (range 
10-30%); 39% inhibition  by anti-GD2 3F8. 
** Control was sham extract purified  by anti-GD2 affinity  chromatogra- 
phy: n =  2; average lysis, 5%; 0% inhibition by anti-GD2 3F8. 
Ganglioside GD2 has been used as a melanoma target for 
T lymphocytes armed with bispecific antibodies combining 
anti-GD2 and anti-CD3 fragments (13). Antibody-blocking 
experiments have also implicated GD2 as a target for LAK 
cells (14). However, CTL recognition of GD2 oligosaccha- 
ride through the classic model of TCR has never been demon- 
strated. Previously,  tumor-associated antigens have been iso- 
lated from EL4 and RBL5 cells (15). However, they appeared 
to reside in glycoprotein fractions. More recently, the tumor 
antigens purified from RMA cells could sensitize RMA-S 
targets for specific lysis by RMA-immune CTL from C57B1/6 
mice (16). The nature of these tumor antigens is still being 
defined (16). Since the repertoire of CTL specificity against 
EL4 or RMA is likely to be heterogeneous, peptide-specific 
CTL might coexist with oligosaccharide-specific  CTL. Al- 
ternatively, although only peptides have so far been identified 
in the MHC class I groove, their conjugation to haptens (e.g., 
TNP  [4,  17,  18]) can  expand  the  repertoire  of antigen 
specificities.  Oligosaccharides, analogous to TNP,  may in- 
teract with or be directly conjugated to peptides.  The inter- 
action of ganglioside and peptides has previously been reported 
(19). Gm was found to associate with gp18 and gp80 on B16 
melanoma cells. CTLs raised against this melanoma did not 
have MHC restriction since they killed across species bar- 
tiers.  Contrary to what  we observed  with GD2 CTL, in 
these previous reports soluble Gvo was able to inhibit these 
melanoma-specific CTL, while specific anti-MHC and anti- 
GM3 antibodies were not inhibitory at microgram per milli- 
liter concentrations. GD3 has also been proposed as a poten- 
tial target for antimelanoma CTL (20). Definitive conclusions 
will require detailed biochemical and structural analyses of 
oligosacchatide-modified peptides derived from tumor cells. 
Haurum et al. (7) recently provided the first evidence  that 
a class I MHC-binding peptide could be modified by O-gly- 
cosylation (O-fl-linked acetyl-glucosamine) within the MHC 
binding region without affecting its binding to MHC class 
I. The resulting peptides were shown to be highly immuno- 
genic and they elicited carbohydrate-specific MHC-restricted 
antiglycopeptide CTL. Proteins bearing the O-B-linked acetyl- 
glucosamine are frequently found in cytosolic and nuclear 
compartments, adding significance  to the potential role of 
oligosacchatide residues in creating neoantigens, loss of toler- 
ance, and development of autoimmunity (7).  The relevance 
of T ceU response to posttranslational modifications, such as 
glycosylation, depends on the identification of naturally oc- 
curring epitopes by direct elution from cells in their normal 
and diseased  states. 
Glycolipids are often thought to be poorly immunogenic 
in both humans and in rodents. The immunogenicity of GD2 
oligosaccharide when presented by EL4 cells is intriguing. 
Previous  studies have identified immunogenic and nonim- 
munogenic variants of EL4 (21). IL-2 release was an unlikely 
explanation since none of these variants were secretors.  Al- 
though suppressor  T  cells were elicited,  they were induced 
by both immunogenic as well as their nonimmunogenic coun- 
terparts. It is possible that other activation molecules expressed 
by EL4 cells may be necessary  for the immunogenicity of 
G,2 (3).  Alternatively, unique peptides that interact with 
GD2 and H-2KbD  b class I antigens that are present on EL4 
or RBL5 cells may be necessary for successful induction of 
GD2-specific CTLs. Lastly, EL4 may function as APC and 
effectively induce Thl that facilitate specific CTL activation 
(22). 
The identification of GD2 oligosaccharide-specific CTL 
may have implications for the understanding of human dis- 
ease states. GD2 is found in the healthy human brain (23) as 
well as a wide spectrum of human tumors, including neuro- 
blastomas (23, 24), osteosarcomas (25), and other soft tissue 
sarcomas  (26),  medulloblastomas (27),  high grade astrocy- 
tomas (27, 28), melanomas (29), small cell lung cancer (30), 
and retinoblastomas (31). Gangliosides are potential targets 
for CTL because  of the high surface antigen density, lack 
of modulation, and relative  homogeneity in most tumors. 
MHC-restricted CTL have been used successfully to target 
immunotherapy (32). Although MHC antigens may be down- 
regulated in many human tumors, IFN-'~ has been very effec- 
tive in inducing MHC expression  (33).  Given the potential 
of CTL in human disease  states  (34-36),  the role of GD2 
oligosaccharide as a target deserves further investigation. 
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